A Phase 2 interventional study of ataciguat (HMR1766) and placebo in Pain, sponsored by Sanofi. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-01.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Pain with a site in Austria — 3 open to participants now, 4 under way, none of them phase 3. Pain · Austria.
Among the 51 studies in Pain with a site in Austria, this one is the 28th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2008, is one of 3 in phase 2, and was the 10th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →3 of the 51 studies in Pain with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+
Medizinische Universität Graz, Institut für Pflegewissenschaft · Sites in Austria
Ages 18+
Medical University of Vienna · Sites in Austria
Ages 18–51 · Women only
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 17 · Phase 4 5
First in 2003; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is close to the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 132 across the 42 interventional studies, 155 across the 9 observational. Of the 43 that completed or were terminated, 15 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 51 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 7 studies filed under Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 51 studies in Pain with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain.
The secondary objective is to assess the safety and tolerability of ataciguat versus placebo.
This study consists of two consecutive 28 day treatment periods which are separated by a 2 week medication free period and a safety follow-up period of 2 weeks after the second treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First period: Ataciguat - Second period: Placebo
Drug: ataciguat (HMR1766) · Drug: placebo
First period: Placebo - Second period: Ataciguat
Drug: ataciguat (HMR1766) · Drug: placebo
oral administration 200mg once daily for 28 days
oral administration once daily for 28 days
Change in average daily pain intensity
Time frame: after 28-days treatment
Responder rate
Time frame: after 28-days treatment
Rescue medication intake
Time frame: during 28-days treatment
Change in Neuropathic Pain Symptom Inventory (NPSI)
Time frame: after 28-days treatment
The record gives a start of Nov 2008, a primary completion of Jun 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ataciguat